Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial

What Was Tested

This randomized controlled trial looks at Vasopressin and Desmopressin.

Desmopressin is an approved medical therapy for the treatment of monosymptomatic primary nocturnal enuresis.

In cases of limited response to desmopressin, the researchers have added anticholinergic therapy to desmopressin (combination therapy).

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Children with lower urinary tract symptoms or bowel dysfunction were excluded, on the basis of a 3-day, 24-hour, frequency-volume chart and elimination record.

Children continued to take desmopressin and were assigned randomly, in a double-blind manner, to receive either extended-release anticholinergic medication or placebo.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

Some participants received a placebo instead of Vasopressin, giving a reference point.

What Was Measured

PubMed files the paper under topics including Antidiuretic Agents, Benzhydryl Compounds, Capsules, Cresols, Deamino Arginine Vasopressin, Muscarinic Antagonists and Nocturnal Enuresis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Pediatrics), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.